Skip to main content

Table 1 Post-trial follow-up (PTFU) in eligible medical trials. Note retention of participants expressed as % lost to follow-up

From: Post-trial follow-up methodology in large randomised controlled trials: a systematic review

1st author, year

Primary outcome for PTFU

RCT name (PTFU name)

No. years PTFUa

Intervention

No. randomised in-trial

No. at the start of PTFU

% participants lost in PTFU

Type of PTFU for primary outcome

  

Post/Q

Clinic

Telephone

Data linkage

Paper records

Other

Alan, 2015

Mortality

ProHOSP

6

CAP antibiotics

1359

925

6

  

Y

 

Y

 

Arbel, 2016

Mortality

BIP

20

Bezafibrate

3090

3090

   

Y

  

Arber, 2011

Cancer, safety

PreSAP

2

Celecoxib

1561

1043

12

     

Y

Avenell, 2012

Mortality

RECORD

3

Vitamin D, Calcium

5292

4394

   

Y

  

Breitner, 2011

Alzheimer’s disease

ADAPT

2

Naproxen, Celecoxib

2528

2233

1

 

Y

    

Bulbulia, 2011

Mortality and morbidity

HPS

6

Simvastatin

20,536

17519

0

Y

  

Y

  

Cauley, 2013

Hip fractures, cancers, CVE and mortality

WHI

5

Calcium plus vitamin D

36,282

29862

1

    

Y

 

Cherry, 2014

Mortality, cancer

ESPIRIT

12

Oestrogen

1017

1017

   

Y

  

Chew, 2013

Progression of age-related macular degeneration

AREDS

5

Antioxidants

4757

3549

 

Y

  

Y

Y

Chowdhury, 2014

Diabetes mellitus, mortality, MACE

ANBP2

7

ACE inhibitor, Thiazide

6083

5678 (6083 linked to death registry)

Y

  

Y

  

Cushman, 2012

MACE, mortality

ALLHAT

13

Amlodipine, lisinopril

32,804

17,722 (CVD), 27,755 (mortality)

   

Y

  

Dienstag, 2011

Progression of Hep C

HALT-C

4

Peginterferon

1050

743

 

Y

    

Eastell, 2015

Bone mineral density

HORIZON-PFT

3

Zoledronic acid

7765

1223

 

Y

   

Y

Ebbing, 2010

Mortality

NORVIT, WENBIT

4

B vitamins

6845

6261

0

   

Y

  

Einstein, 2011

Safety, immunogenicity

2

HPV vaccine

1106

671

0

 

Y

   

Erdmann, 2014

Mortality, MI, stroke, MACE, (composite)

PROactive

3

Pioglitazone

5238

3599

9

 

Y

Y

 

Y

Y

Ezzedine, 2010

Skin cancer

SU.VI.MAX

5

Antioxidant vitamins

12,741

11054

2

Y

   

Y

 

Flossman, 2007

Colorectal cancer

UK-TIA

20

Aspirin

2449

2249

   

Y

Y

 

Colorectal cancer

BDAT

20

Aspirin

5139

5139

   

Y

Y

 

Ford, 2016

Mortality and morbidity

WOSCOPS

20

Pravastatin

6595

5778

   

Y

  

Gerstein, 2016

MACE, mortality (composite)

ACCORD (ACCORDIAN)

3

Intensive glucose control

10,251

8601

 

Y

Y

   

Gluud, 2008

Mortality

CLARICOR

3

Clarithromycin

4373

4029

1

   

Y

  

Gordon, 2012

Efficacy and safety

REVEAL

2

Adalimumab

1212

575

7

 

Y

    

Grau, 2009

Adenomas

AFPPS

4

Aspirin

1121

1007

14

Y

Y

    

Grubb, 2013

Cancer

REDUCE

2

Dutasteride

8231

2751

 

Y

Y

   

Hackshaw, 2011

Event-free survival

OVER 50S TRIAL

10

Tamoxifen

3449

3449

   

Y

  

Hague, 2016

Mortality, cancer

LIPID

10

Pravastatin

9014

7721

0

Y

Y

Y

Y

Y

 

Hayashino, 2009

Diabetes mellitus

PHI1

17

Aspirin

22,071

22,071

Y

    

Y

Hayward, 2015

MACE

VADT

5

Intensive glucose lowering vs standard therapy

1791

1791

22

Y

  

Y

  

Holman, 2008

Macrovascular outcomes

UKPDS

10

Intensive glycaemic control

3867

3277

20

Y

Y

 

Y

  

Hornslien, 2015

Stroke, MI, mortality

SCAST

3

Candesartan

2029

1286

2

   

Y

  

Investigators, 2011

Diabetes mellitus

DREAM (DREAM ON)

2

Rosiglitazone, ramipril

5269

1653

18

 

Y

    

Johnson, 2015

Vaccine efficacy

SPS (LTPS)

4

Vaccine

38,543

6867

6

 

Y

Y

   

Jones, 2015

Cancer, bone fractures

RECORD

4

Rosiglitazone

4447

2546

1

  

Y

Y

Y

 

Kostis, 2011

Mortality

SHEP

13

Chlorthalidone

4736

   

Y

  

Krane, 2016

MACE, mortality (composite)

4D

8

Atorvastatin

1255

637

3

Y

     

Lai, 2014

Mortality, liver cancer

ATBC

16

α-tocopherol,β-carotene

29,133

29105

   

Y

  

Laterre, 2007

Mortality

ADDRESS

1

Drotrecogin-α

2640

2621

9

Y

 

Y

 

Y

 

Leslie, 2011

Mortality

ENIGMA

4

Nitrous oxide

2050

2002

17

  

Y

 

Y

 

Leslie, 2015

MACE, mortality

ENIGMA-II

1

Nitrous oxide

7112

6651

12

  

Y

 

Y

 

Lewis, 2011

MACE

CAIFOS

5

Calcium

1510

1510

   

Y

  

Lloyd, 2013

MACE, cancers, mortality

PROSPER

3

Pravastatin

5804

5188

   

Y

  

Menne, 2014

Long-term micro, macrovascular benefit

ROADMAP (ROADMAP OFU)

3

Olmesartan medoxomil

4449

2198

0

 

Y

    

Ogihara, 2011

MACE, cancer, mortality

CASE-J (CASE-J Ex)

3

Candesartan, amlodipine

4728

2232

2

 

Y

    

Radford, 2014

Bone mineral density

Auckland Calcium Study

5

Calcium

1471

1408

17

  

Y

Y

  

Rothwell, 2010

Colorectal cancer

Thrombosis Prev Trial, Swedish Aspirin Low Dose Trial, Dutch TIA Aspirin Trial, UK-Tia Aspirin Trial, British Doctors Aspirin Trial

12, 13, 17, 18, 20

Aspirin

16,488

14033

 

Y

 

Y

Y

 

Tenkanen, 2006

MACE, cancer, mortality

Helsinki Heart Study

10

Gemfibrozil

4081

4081

0

Y

  

Y

  

Wang, 2015

Fracture incidence

NIT

16

Vitamins (14), minerals (12)

3318

3318

1

  

Y

 

Y

 

Weston, 2011

Persistence of antibodies

106316

3

Vaccine dip, pert, tetanus

2284

1505

 

Y

    

Whiteley, 2014

Disability

IST-3

1

Alteplase

3035

2348

2

   

Y

  

Zoungas, 2014

Mortality

ADVANCE (ADVANCE-ON)

6

Perindopril, indapamide

11,140

8494

 

Y

Y

   
  1. where a is number of years (median/mean/max) published in the cited paper, years followed up to the nearest whole number, % participants lost to the nearest whole number,‘–’ no data available or not applicable where mortality records were sought, CVD cardiovascular disease, MACE major adverse cardiovascular events ± revascularisation, MI myocardial infarction. Where 0 participants have been lost to follow-up this has been confirmed either in the cited paper or directly with the corresponding trialist